Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H23NO7S.2Na |
| Molecular Weight | 443.422 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].COCCOCCOCCOC1=CC=CC(C2=N[C@](C)(CS2)C([O-])=O)=C1[O-]
InChI
InChIKey=ZGUSTINUKQHFCO-JPKZNVRTSA-L
InChI=1S/C18H25NO7S.2Na/c1-18(17(21)22)12-27-16(19-18)13-4-3-5-14(15(13)20)26-11-10-25-9-8-24-7-6-23-2;;/h3-5,20H,6-12H2,1-2H3,(H,21,22);;/q;2*+1/p-2/t18-;;/m1../s1
Deferitazole is an iron chelator, developed by the FerroKin BioSciences (later acquired by Shire, and then by Takeda). Deferitazole is a member of the desazadesferrithiocin class of siderophore-related tridentate chelators. It binds Fe(III) with very high affinity and selectivity over Fe(II) and other biologically important metals. Deferitazole was investigated in phase 2 clinical trials in patients with iron overload due to repeated red blood cell transfusion and beta-thalassemia, however, the development of the drug was discontinued. In preclinical models, deferitazole demonstrated efficacy for the treatment and prevention of malaria.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
U5SD55XZY8
Created by
admin on Mon Mar 31 23:06:41 GMT 2025 , Edited by admin on Mon Mar 31 23:06:41 GMT 2025
|
PRIMARY | |||
|
71599794
Created by
admin on Mon Mar 31 23:06:41 GMT 2025 , Edited by admin on Mon Mar 31 23:06:41 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
